Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma

Shanhao Tang, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Yin Lu, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Pisheng Zhang, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Dong Chen, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Xuhui Liu, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Xiaohong Du, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Junjie Cao, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Peipei Ye, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Lieguang Chen, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Shuangyue Li, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Keya Sha, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Xian Xu Zhuang, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China.
Yiyu Xie, Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China; Yale New Haven Health/Bridgeport Hospital, Bridgeport, 06610, USA.
Xiaojin Wu, Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, 215006, China. Electronic address: wuxiaojin@suda.edu.cn.
Renzhi Pei, Department of Hematology, the Affiliated People's Hospital of Ningbo University, Ningbo, 315040, China. Electronic address: peirz@163.com.

Document Type

Article

Publication Title

Leukemia research

Abstract

In order to investigate the efficacy of lenalidomide, bortezomib and dexamethasone (VRD) induction chemotherapy regimen combined with tandem autologous stem cell transplantation (ASCT) in treating multi-hit multiple myeloma (MM), we analyzed 252 cases of newly diagnosed MM treated with the bortezomib-containing induction chemotherapy from June 2016 to June 2019. According to the fluorescence in situ hybridization (FISH) results on diagnosis, the patients were divided into multi-hit MM group (47 cases), single-hit MM group (81 cases), and standard-risk group (124 cases). Our analysis showed that R-ISS stageⅢ in transplantation group and R-ISS stageⅢ, multi-hit and VGPR or above was not achieved at the fourth cycle of chemotherapy in non-transplantation group were independent factors for poor prognosis by univariate and multivariate analyses. Moreover, the overall response rate (ORR) of VRD induction chemotherapy group was significantly higher than that of the non-VRD group in the single-hit and multi-hit groups (P = 0.021, P = 0.032); In terms of ASCT, tandem-ASCT can significantly improve the 2-year PFS (77.8 ± 3.9 %) and OS (83.3 ± 5.6 %) of multi-hit MM (P = 0.024, P = 0.037), while single-ASCT only has a limited effect on PFS (61.5 ± 3.0 %) and OS (71.9 ± 4.5 %) (P = 0.115, P = 0.155).

First Page

106710

DOI

10.1016/j.leukres.2021.106710

Publication Date

11-1-2021

Identifier

34619433 (pubmed); 10.1016/j.leukres.2021.106710 (doi); S0145-2126(21)01711-2 (pii)

This document is currently not available here.

Share

COinS